Eterna Financial Statements From 2010 to 2026

Eterna Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 5.8 M 6.1 M 17.8 M Very volatile Other Current Liabilities 861 K 906.3 K 2.2 M Slightly volatile Total Current Liabilities 5.7 M 3.4 M 5.4 M Pretty Stable Total Stockholder Equity 1.5 M 1.5 M 7.7 M Slightly volatile Non Current Assets Total 3.2 M 3.4 M 9.6 M Very volatile Non Currrent Assets Other 100.9 K 106.2 K 2.1 M Slightly volatile Common Stock Shares Outstanding 1.1 M 1 M 245.7 K Slightly volatile Liabilities And Stockholders Equity 5.8 M 6.1 M 17.8 M Very volatile Non Current Liabilities Total 688.3 K 724.5 K 4.8 M Pretty Stable Other Current Assets 159 K 167.4 K 2.2 M Slightly volatile Total Liabilities 3.9 M 4.1 M 10 M Pretty Stable Total Current Assets 2 M 2.1 M 8.1 M Slightly volatile Short and Long Term Debt Total 747.3 K 786.6 K 5.5 M Pretty Stable Property Plant And Equipment Net 824.8 K 868.2 K 4.8 M Pretty Stable Current Deferred Revenue 207.6 K 218.5 K 868.9 K Slightly volatile Accounts Payable 2.1 M 2 M 972.2 K Slightly volatile Cash 1.9 M 2 M 5.2 M Very volatile Cash And Short Term Investments 1.9 M 2 M 5.2 M Very volatile Net Receivables 659.9 K 393.3 K 830 K Slightly volatile Good Will 1.5 M 2.4 M 1.4 M Slightly volatile Short Term Debt 226.1 K 238.1 K 1.4 M Very volatile Intangible Assets 7.2 M 6.9 M 3.1 M Slightly volatile Common Stock 280.8 K 295.6 K 1.7 M Very volatile Other Assets 4.8 M 6 M 3.2 M Slightly volatile Other Liabilities 2 M 1.9 M 1 M Slightly volatile Net Tangible Assets 12.1 M 11.6 M 9.7 M Slightly volatile Deferred Long Term Liabilities 5.1 M 5.4 M 6.4 M Slightly volatile Property Plant Equipment 1.7 M 1.5 M 834.4 K Slightly volatile Long Term Debt 8.2 M 7.8 M 2 M Slightly volatile Capital Lease Obligations 747.3 K 786.6 K 3.8 M Pretty Stable Net Invested Capital 1.5 M 1.5 M 7.5 M Slightly volatile Property Plant And Equipment Gross 1 M 1.1 M 4.2 M Pretty Stable Short and Long Term Debt 1.3 M 2 M 944.1 K Slightly volatile Capital Stock 220.6 K 232.2 K 16.8 M Slightly volatile Non Current Liabilities Other 130 K 136.8 K 1.2 M Pretty Stable
Eterna Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Other Operating Expenses 32.9 M 18.7 M 29.8 M Very volatile Total Operating Expenses 29.7 M 18.6 M 26.8 M Very volatile Depreciation And Amortization 1.4 M 1.5 M 3.4 M Slightly volatile Interest Expense 8.2 M 7.8 M 1.5 M Slightly volatile Cost Of Revenue 82.1 K 86.4 K 2.9 M Pretty Stable Research Development 5.2 M 5.3 M 2.9 M Slightly volatile Selling General Administrative 13.7 M 15.1 M 7.3 M Slightly volatile Reconciled Depreciation 2 M 1.9 M 486 K Slightly volatile Selling And Marketing Expenses 800 900 982 Slightly volatile
Eterna Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Stock Based Compensation 1.3 M 1.4 M 29.8 M Slightly volatile Depreciation 1.4 M 1.5 M 233.2 M Slightly volatile Begin Period Cash Flow 14.1 M 13.4 M 6.8 M Slightly volatile Issuance Of Capital Stock 972.1 K 1 M 8.3 M Pretty Stable Other Cashflows From Investing Activities 3.4 K 3.6 K 99.6 K Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 270 194 541 Slightly volatile Dividend Yield 1.0E-4 1.0E-4 1.0E-4 Slightly volatile PTB Ratio 58.81 66.26 67.4587 Pretty Stable Days Sales Outstanding 301 247 594 Slightly volatile Book Value Per Share 0.0654 0.0689 51.3649 Slightly volatile Stock Based Compensation To Revenue 2.85 3.0 15.5393 Slightly volatile Capex To Depreciation 0.43 0.26 0.4273 Slightly volatile PB Ratio 58.81 66.26 67.4587 Pretty Stable EV To Sales 327 192 663 Slightly volatile Inventory Turnover 6.8 6.48 4.7176 Slightly volatile Days Of Inventory On Hand 55.42 58.34 101 Slightly volatile Payables Turnover 0.0609 0.0641 27.2765 Slightly volatile Sales General And Administrative To Revenue 24.65 25.95 181 Slightly volatile Research And Ddevelopement To Revenue 6.76 7.12 21.7696 Slightly volatile Capex To Revenue 0.6 0.57 0.2089 Slightly volatile Cash Per Share 0.0665 0.07 40.8054 Slightly volatile Days Payables Outstanding 6.2 K 5.9 K 1.7 K Slightly volatile Intangibles To Total Assets 0.37 0.35 0.1632 Slightly volatile Current Ratio 1.34 0.72 1.6248 Pretty Stable Receivables Turnover 1.45 1.53 15.0506 Slightly volatile Shareholders Equity Per Share 0.0654 0.0689 51.3649 Slightly volatile Debt To Equity 0.34 0.36 2.2012 Very volatile Capex Per Share 0.0142 0.0149 17.2936 Slightly volatile Revenue Per Share 0.0224 0.0236 273 Slightly volatile Interest Debt Per Share 0.29 0.3 89.0877 Slightly volatile Debt To Assets 0.14 0.15 0.3516 Slightly volatile Graham Number 20.91 23.53 25.6786 Slightly volatile Operating Cycle 364 247 630 Slightly volatile Price Book Value Ratio 58.81 66.26 67.4587 Pretty Stable Days Of Payables Outstanding 6.2 K 5.9 K 1.7 K Slightly volatile Company Equity Multiplier 3.73 2.79 4.4099 Pretty Stable Long Term Debt To Capitalization 0.91 0.86 0.4756 Very volatile Total Debt To Capitalization 0.51 0.33 0.5156 Slightly volatile Debt Equity Ratio 0.34 0.36 2.2012 Very volatile Quick Ratio 1.2 0.72 1.5158 Pretty Stable Cash Ratio 0.91 0.53 0.9377 Pretty Stable Days Of Inventory Outstanding 55.42 58.34 101 Slightly volatile Days Of Sales Outstanding 301 247 594 Slightly volatile Price To Book Ratio 58.81 66.26 67.4587 Pretty Stable Fixed Asset Turnover 0.84 0.89 3.5948 Slightly volatile Debt Ratio 0.14 0.15 0.3516 Slightly volatile Price Sales Ratio 270 194 541 Slightly volatile Asset Turnover 0.12 0.13 0.8567 Slightly volatile Price Fair Value 58.81 66.26 67.4587 Pretty Stable

Eterna Fundamental Market Drivers

Eterna Upcoming Events

About Eterna Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:

How To Invest In Eterna Details

Is Eterna Stock a good investment? Details

What is Eterna Therapeutics' Net Worth? Details

Largest Biotechnology Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details